BGLC
BioNexus Gene Lab Corp.
Medical - Diagnostics & Research
Market Cap$4M
5Y Perf.-98.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BGLC vs RNAZ
Revenue, margins, valuation, and 5-year total return — side by side.
RNAZ
TransCode Therapeutics, Inc.
Biotechnology
Market Cap$6M
5Y Perf.-100.0%
BGLC vs RNAZ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BGLC | RNAZ |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $4M | $6M |
| Revenue (TTM) | $9M | $0.00 |
| Net Income (TTM) | $-2M | $-27M |
| Gross Margin | 14.8% | — |
| Operating Margin | -24.8% | — |
| Total Debt | $211K | $38K |
| Cash & Equiv. | $4M | $6M |
BGLC vs RNAZ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BGLC
RNAZ
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| BioNexus Gene Lab C… (BGLC) | 100 | 1.5 | -98.5% |
| TransCode Therapeut… (RNAZ) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BGLC vs RNAZ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNAZ leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. BioNexus Gene Lab Corp. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BGLC
BioNexus Gene Lab Corp.
The Long-Run Compounder
BGLC is the clearest fit if your priority is long-term compounding.
- -99.2% 10Y total return vs RNAZ's -100.0%
- -2.7% revenue growth vs RNAZ's -87.4%
- -22.8% vs RNAZ's -25.4%
Best for: long-term compounding
RNAZ
TransCode Therapeutics, Inc.
The Income Pick
RNAZ carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.80
- EPS growth 98.6%
- Lower volatility, beta 0.80, current ratio 2.56x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BGLC | -2.7% revenue growth vs RNAZ's -87.4% |
| Quality / Margins | RNAZ | -0.4% margin vs BGLC's -24.3% |
| Stability / Safety | RNAZ | Beta 0.80 vs BGLC's 1.56 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BGLC | -22.8% vs RNAZ's -25.4% |
| Efficiency (ROA) | RNAZ | -0.5% ROA vs BGLC's -30.1% |
BGLC vs RNAZ — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBGLCLAGGINGRNAZ
RNAZTransCode Therapeutic…
2leads
BGLCBioNexus Gene Lab Cor…
3leads
6 Total Categories
CATEGORYLEADERvs RNAZMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BGLC1/1
Valuation MetricsMultiples, price ratios, and targets
BGLC1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNAZ5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
BGLC5/6
Risk & VolatilityBeta, volatility, and downside exposure
RNAZ2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BGLC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BGLC and RNAZ operate at a comparable scale, with $9M and $0 in trailing revenue.
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| RevenueTrailing 12 months | $9M | $0 |
| EBITDAEarnings before interest/tax | -$2M | -$17M |
| Net IncomeAfter-tax profit | -$2M | -$27M |
| Free Cash FlowCash after capex | -$3M | -$15M |
| Gross MarginGross profit ÷ Revenue | +14.8% | — |
| Operating MarginEBIT ÷ Revenue | -24.8% | — |
| Net MarginNet income ÷ Revenue | -24.3% | — |
| FCF MarginFCF ÷ Revenue | -30.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +48.0% | -380.7% |
BGLC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BGLC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| Market CapShares × price | $4M | $6M |
| Enterprise ValueMkt cap + debt − cash | -$465,880 | $329,787 |
| Trailing P/EPrice ÷ TTM EPS | -2.29x | -0.16x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.39x | — |
| Price / BookPrice ÷ Book value/share | 0.44x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
BGLC leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RNAZ leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
RNAZ delivers a -1.9% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-34 for BGLC. On the Piotroski fundamental quality scale (0–9), RNAZ scores 4/9 vs BGLC's 2/9, reflecting mixed financial health.
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -33.7% | -1.9% |
| ROA (TTM)Return on assets | -30.1% | -0.5% |
| ROICReturn on invested capital | -29.4% | — |
| ROCEReturn on capital employed | -17.2% | -5.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$4M | -$6M |
| Cash & Equiv.Liquid assets | $4M | $6M |
| Total DebtShort + long-term debt | $210,557 | $38,291 |
| Interest CoverageEBIT ÷ Interest expense | -148.94x | -3431.07x |
RNAZ leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
BGLC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BGLC five years ago would be worth $143 today (with dividends reinvested), compared to $0 for RNAZ. Over the past 12 months, BGLC leads with a -22.8% total return vs RNAZ's -25.4%. The 3-year compound annual growth rate (CAGR) favors BGLC at -62.7% vs RNAZ's -96.4% — a key indicator of consistent wealth creation.
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| YTD ReturnYear-to-date | -47.7% | -1.1% |
| 1-Year ReturnPast 12 months | -22.8% | -25.4% |
| 3-Year ReturnCumulative with dividends | -94.8% | -100.0% |
| 5-Year ReturnCumulative with dividends | -98.6% | -100.0% |
| 10-Year ReturnCumulative with dividends | -99.2% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -62.7% | -96.4% |
BGLC leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
RNAZ leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RNAZ is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than BGLC's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNAZ currently trades 34.9% from its 52-week high vs BGLC's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 0.80x |
| 52-Week HighHighest price in past year | $15.60 | $20.99 |
| 52-Week LowLowest price in past year | $1.92 | $6.08 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +34.9% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 5K | 8K |
RNAZ leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BGLCBioNexus Gene Lab… | RNAZTransCode Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BGLC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). RNAZ leads in 2 (Profitability & Efficiency, Risk & Volatility).
Best OverallBioNexus Gene Lab Corp. (BGLC)Leads 3 of 6 categories
Loading custom metrics...
BGLC vs RNAZ: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BGLC or RNAZ?
Over the past 5 years, BioNexus Gene Lab Corp.
(BGLC) delivered a total return of -98. 6%, compared to -100. 0% for TransCode Therapeutics, Inc. (RNAZ). Over 10 years, the gap is even starker: BGLC returned -99. 2% versus RNAZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BGLC or RNAZ?
By beta (market sensitivity over 5 years), TransCode Therapeutics, Inc.
(RNAZ) is the lower-risk stock at 0. 80β versus BioNexus Gene Lab Corp. 's 1. 56β — meaning BGLC is approximately 95% more volatile than RNAZ relative to the S&P 500.
03Which is growing faster — BGLC or RNAZ?
On earnings-per-share growth, the picture is similar: TransCode Therapeutics, Inc.
grew EPS 98. 6% year-over-year, compared to 41. 2% for BioNexus Gene Lab Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BGLC or RNAZ?
TransCode Therapeutics, Inc.
(RNAZ) is the more profitable company, earning 0. 0% net margin versus -16. 8% for BioNexus Gene Lab Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNAZ leads at 0. 0% versus -16. 5% for BGLC. At the gross margin level — before operating expenses — BGLC leads at 13. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BGLC or RNAZ?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BGLC or RNAZ better for a retirement portfolio?
For long-horizon retirement investors, TransCode Therapeutics, Inc.
(RNAZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). BioNexus Gene Lab Corp. (BGLC) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNAZ: -100. 0%, BGLC: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BGLC and RNAZ?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.